Doptelet for aplastic anemia – pro
Nomoto M, Pastino G, Rege B, Aluri J, Ferry J, Han D: Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Clin Pharmacol Drug Dev. 2018 Feb;7(2):188-195
Wang H, He G, Jia J, Liu M, Liu H, Wang T, Liu C, Fu R. Efficacy and safety of avatrombopag in aplastic anemia patients with liver disease. J Transl Int Med. 2023 May 7;11(1):90-93. doi: 10.2478/jtim-2023-0006. PMID: 37533842; PMCID: PMC10393059.
Ting Zhang, Qingling Yu, Xiaoyu Chen, Hui Yang, Yuemin Gong, Yawen Zhang, Xiaoqing Liu, Zhinan Yang, Yu Fang, Xue Yan, Xuan Zhou, Jinning Shi, Guangsheng He,Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag. 2024, Frontiers in Immunology doi: 10.3389/fimmu.2024.1393829